CA2611809C - Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells - Google Patents
Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells Download PDFInfo
- Publication number
- CA2611809C CA2611809C CA2611809A CA2611809A CA2611809C CA 2611809 C CA2611809 C CA 2611809C CA 2611809 A CA2611809 A CA 2611809A CA 2611809 A CA2611809 A CA 2611809A CA 2611809 C CA2611809 C CA 2611809C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- bmp
- cell
- pluripotent stem
- activin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 437
- 210000001778 pluripotent stem cell Anatomy 0.000 title claims abstract description 67
- 241000288906 Primates Species 0.000 title abstract description 67
- 230000004069 differentiation Effects 0.000 title abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 79
- 238000012258 culturing Methods 0.000 claims abstract description 42
- 239000002609 medium Substances 0.000 claims description 60
- 230000000747 cardiac effect Effects 0.000 claims description 39
- 108010023082 activin A Proteins 0.000 claims description 23
- 239000000758 substrate Substances 0.000 claims description 19
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 16
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 16
- 108010010803 Gelatin Proteins 0.000 claims description 13
- 229920000159 gelatin Polymers 0.000 claims description 13
- 239000008273 gelatin Substances 0.000 claims description 13
- 235000019322 gelatine Nutrition 0.000 claims description 13
- 235000011852 gelatine desserts Nutrition 0.000 claims description 13
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 12
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 12
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 9
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 9
- 210000002242 embryoid body Anatomy 0.000 claims description 9
- 238000003306 harvesting Methods 0.000 claims description 6
- 239000012679 serum free medium Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 108010085895 Laminin Proteins 0.000 claims description 4
- 102000007547 Laminin Human genes 0.000 claims description 4
- 102100037362 Fibronectin Human genes 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 108010031318 Vitronectin Proteins 0.000 claims description 3
- 102100035140 Vitronectin Human genes 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 abstract description 9
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 41
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 41
- 229940112869 bone morphogenetic protein Drugs 0.000 description 41
- 108010059616 Activins Proteins 0.000 description 37
- 239000000488 activin Substances 0.000 description 37
- 102100026818 Inhibin beta E chain Human genes 0.000 description 36
- 210000004413 cardiac myocyte Anatomy 0.000 description 35
- 210000001519 tissue Anatomy 0.000 description 28
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 25
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 21
- 210000001671 embryonic stem cell Anatomy 0.000 description 20
- 239000012091 fetal bovine serum Substances 0.000 description 18
- 238000010186 staining Methods 0.000 description 18
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 15
- 102000004142 Trypsin Human genes 0.000 description 15
- 108090000631 Trypsin Proteins 0.000 description 15
- 239000012588 trypsin Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 108010082117 matrigel Proteins 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 10
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 10
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 10
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 10
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 10
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 9
- 230000037020 contractile activity Effects 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 239000012583 B-27 Supplement Substances 0.000 description 8
- 241000283707 Capra Species 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 210000002064 heart cell Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000008602 contraction Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 6
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 6
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 6
- 102000029816 Collagenase Human genes 0.000 description 6
- 108060005980 Collagenase Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 102000004903 Troponin Human genes 0.000 description 6
- 108090001027 Troponin Proteins 0.000 description 6
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 6
- 229960002424 collagenase Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 230000000737 periodic effect Effects 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000010009 beating Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000002459 blastocyst Anatomy 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000003716 mesoderm Anatomy 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- -1 NIcx2.5 Proteins 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 230000004077 genetic alteration Effects 0.000 description 3
- 231100000118 genetic alteration Toxicity 0.000 description 3
- 210000001654 germ layer Anatomy 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 2
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 2
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 101000595198 Homo sapiens Podocalyxin Proteins 0.000 description 2
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 2
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 description 2
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 description 2
- 102100032970 Myogenin Human genes 0.000 description 2
- 108010056785 Myogenin Proteins 0.000 description 2
- 102000036675 Myoglobin Human genes 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- 108050000637 N-cadherin Proteins 0.000 description 2
- 101150114527 Nkx2-5 gene Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 102000002584 Octamer Transcription Factor-3 Human genes 0.000 description 2
- 108010068425 Octamer Transcription Factor-3 Proteins 0.000 description 2
- 102100036031 Podocalyxin Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000004987 Troponin T Human genes 0.000 description 2
- 108090001108 Troponin T Proteins 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000007555 cardiovascular defect Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000030968 tissue homeostasis Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101000993093 Arabidopsis thaliana Heat stress transcription factor B-2a Proteins 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 108010002947 Connectin Proteins 0.000 description 1
- 102000004726 Connectin Human genes 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 102000001045 Connexin 43 Human genes 0.000 description 1
- 108010069241 Connexin 43 Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102000006312 Cyclin D2 Human genes 0.000 description 1
- 108010058544 Cyclin D2 Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101150094793 Hes3 gene Proteins 0.000 description 1
- 101150029234 Hes5 gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000588969 Homo sapiens Putative uncharacterized protein MYH16 Proteins 0.000 description 1
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 1
- 101000843556 Homo sapiens Transcription factor HES-1 Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102100031790 Myelin expression factor 2 Human genes 0.000 description 1
- 101710107751 Myelin expression factor 2 Proteins 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102100032974 Putative uncharacterized protein MYH16 Human genes 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 101100016889 Rattus norvegicus Hes2 gene Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 1
- 102100030798 Transcription factor HES-1 Human genes 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- 101150046432 Tril gene Proteins 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 108010023079 activin B Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000677 aggregate cell Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 108010016628 ameroid Proteins 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000001426 cardiotropic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000004039 endoderm cell Anatomy 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000012248 genetic selection Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000009067 heart development Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960000554 metrizamide Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000016489 regulation of striated muscle contraction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000002235 sarcomere Anatomy 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000188 sister chromatid exchange Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940005267 urate oxidase Drugs 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69314105P | 2005-06-22 | 2005-06-22 | |
| US60/693,141 | 2005-06-22 | ||
| PCT/US2006/024060 WO2007002136A2 (en) | 2005-06-22 | 2006-06-20 | Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2611809A1 CA2611809A1 (en) | 2007-01-04 |
| CA2611809C true CA2611809C (en) | 2018-06-19 |
Family
ID=37595761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2611809A Expired - Fee Related CA2611809C (en) | 2005-06-22 | 2006-06-20 | Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9062289B2 (enExample) |
| EP (1) | EP1910518B1 (enExample) |
| JP (2) | JP5560393B2 (enExample) |
| KR (2) | KR20130099253A (enExample) |
| CN (1) | CN101228264B (enExample) |
| AU (1) | AU2006262329B2 (enExample) |
| CA (1) | CA2611809C (enExample) |
| GB (1) | GB2441718B (enExample) |
| IL (1) | IL187611A (enExample) |
| WO (1) | WO2007002136A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2412383A1 (en) * | 2006-07-28 | 2012-02-01 | Children's Memorial Hospital | Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells |
| US8106004B2 (en) * | 2006-07-28 | 2012-01-31 | Children's Memorial Hospital | Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells |
| WO2009120762A2 (en) | 2008-03-27 | 2009-10-01 | Mount Sinai School Of Medicine Of New York University | Human cardiovascular progenitor cells |
| CA2777552C (en) | 2009-10-19 | 2019-05-21 | Cellular Dynamics International, Inc. | Cardiomyocyte production |
| US9181529B2 (en) | 2010-10-19 | 2015-11-10 | Cellular Dynamics International, Inc. | Titration of differentiation medium components |
| JP6090855B2 (ja) | 2010-11-17 | 2017-03-08 | 国立大学法人京都大学 | 心筋細胞および／または心筋前駆細胞増殖剤ならびに心筋細胞および／または心筋前駆細胞の増殖方法 |
| US20140329314A1 (en) | 2011-03-29 | 2014-11-06 | Christopher O'Sullivan | Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells |
| US9487752B2 (en) | 2011-03-30 | 2016-11-08 | Cellular Dynamics International, Inc. | Priming of pluripotent stem cells for neural differentiation |
| JP5840855B2 (ja) | 2011-03-30 | 2016-01-06 | 学校法人東京女子医科大学 | 胚性幹細胞から心筋シートを製造する方法 |
| US9164093B2 (en) | 2011-03-31 | 2015-10-20 | Iheart Japan Corporation | Cardiomyocyte marker |
| MY170940A (en) | 2011-06-16 | 2019-09-19 | Ge Video Compression Llc | Entropy coding of motion vector differences |
| KR101966208B1 (ko) | 2011-07-21 | 2019-04-09 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 환자로부터 유도 만능 줄기 세포들로부터의 심근 세포 및 그 사용 방법 |
| GB201121101D0 (en) * | 2011-12-08 | 2012-01-18 | Nhs Blood & Transplant | A method of preparing isolated cells and uses |
| EP2826855B1 (en) | 2012-03-15 | 2018-08-29 | iHeart Japan Corporation | Myocardial sheet |
| JP6373253B2 (ja) | 2012-07-17 | 2018-08-15 | 国立大学法人京都大学 | 新規心筋細胞マーカー |
| JP6429280B2 (ja) | 2013-05-14 | 2018-11-28 | 国立大学法人京都大学 | 効率的な心筋細胞の誘導方法 |
| CN105247041B (zh) | 2013-05-31 | 2018-04-20 | 爱心细胞有限公司 | 组入有水凝胶的层叠细胞膜片 |
| WO2014192312A1 (ja) * | 2013-05-31 | 2014-12-04 | 国立大学法人 東京医科歯科大学 | 正常な内向きのカリウム電流特性を有するｉＰＳ細胞由来心筋モデル細胞 |
| KR102423106B1 (ko) | 2013-06-11 | 2022-07-21 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | SC-β 세포 및 조성물 그리고 그 생성 방법 |
| EP3121276B1 (en) | 2014-03-20 | 2019-04-17 | Kyoto University | Cardiomyocyte sorting method |
| EP3140395B1 (en) * | 2014-05-06 | 2020-01-22 | F. Hoffmann-La Roche AG | Method for differentiation of pluripotent stem cells into cardiomyocytes |
| JP6265515B2 (ja) * | 2014-09-16 | 2018-01-24 | 国立大学法人大阪大学 | 多能性幹細胞由来心筋細胞集団の製造方法 |
| WO2016100930A1 (en) | 2014-12-18 | 2016-06-23 | President And Fellows Of Harvard College | Methods for generating stem cell-derived b cells and methods of use thereof |
| WO2016100909A1 (en) | 2014-12-18 | 2016-06-23 | President And Fellows Of Harvard College | METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF |
| WO2016100898A1 (en) | 2014-12-18 | 2016-06-23 | President And Fellows Of Harvard College | Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof |
| US10556388B2 (en) * | 2015-04-22 | 2020-02-11 | Eastman Chemical Company | Polyester-based tape composites for wood reinforcement |
| HK1254190A1 (zh) | 2015-05-08 | 2019-07-12 | President And Fellows Of Harvard College | 通用供体干细胞和相关方法 |
| AU2018370029B2 (en) | 2017-11-15 | 2024-11-07 | Vertex Pharmaceuticals Incorporated | Islet cell manufacturing compositions and methods of use |
| WO2019189545A1 (ja) | 2018-03-30 | 2019-10-03 | 国立大学法人京都大学 | 細胞の製造方法 |
| US11401264B2 (en) | 2018-03-30 | 2022-08-02 | Orizuru Therapeutics, Inc. | Heterocyclic compound |
| WO2019189554A1 (ja) | 2018-03-30 | 2019-10-03 | 国立大学法人京都大学 | 心筋細胞成熟促進剤 |
| EP3833365A4 (en) | 2018-08-10 | 2022-05-11 | Vertex Pharmaceuticals Incorporated | Stem cell derived islet differentiation |
| TWI837161B (zh) | 2018-08-10 | 2024-04-01 | 日商武田藥品工業股份有限公司 | 陽離子性脂質 |
| CN112639111B (zh) | 2018-08-10 | 2023-07-21 | 国立大学法人京都大学 | 使用阳离子性脂质的转染心肌细胞的方法 |
| EP4017508A1 (en) | 2019-08-23 | 2022-06-29 | Sana Biotechnology, Inc. | Cd24 expressing cells and uses thereof |
| MX2023001831A (es) | 2020-08-13 | 2023-06-29 | Sana Biotechnology Inc | Métodos de tratamiento de pacientes sensibilizados con células hipoinmunogénicas y métodos y composiciones asociados. |
| KR20240013135A (ko) | 2021-05-27 | 2024-01-30 | 사나 바이오테크놀로지, 인크. | 조작된 hla-e 또는 hla-g를 포함하는 저면역원성 세포 |
| AU2022309875A1 (en) | 2021-07-14 | 2024-01-25 | Sana Biotechnology, Inc. | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells |
| EP4384598A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| WO2023019225A2 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| EP4384544A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| IL310702A (en) | 2021-08-11 | 2024-04-01 | Sana Biotechnology Inc | Inducible systems for altering gene expression in hypoimmunogenic cells |
| KR20230073749A (ko) | 2021-11-19 | 2023-05-26 | 주식회사 로킷헬스케어 | 박동형 심근 패치의 제조방법 및 이를 이용하여 제조된 박동형 심근 패치 |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| WO2024243236A2 (en) | 2023-05-22 | 2024-11-28 | Sana Biotechnology, Inc. | Methods of delivery of islet cells and related methods |
| WO2025054202A1 (en) | 2023-09-05 | 2025-03-13 | Sana Biotechnology, Inc. | Method of screening a sample comprising a transgene with a unique barcode |
| WO2025151838A1 (en) | 2024-01-12 | 2025-07-17 | Sana Biotechnology, Inc. | Safety switches to control in vitro and in vivo proliferation of cell therapy products |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4491632A (en) | 1979-10-22 | 1985-01-01 | The Massachusetts General Hospital | Process for producing antibodies to hepatitis virus and cell lines therefor |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| DE3167442D1 (en) | 1980-07-07 | 1985-01-10 | Nat Res Dev | Improvements in or relating to cell lines |
| GB2197915B (en) | 1986-11-19 | 1990-11-14 | Rolls Royce Plc | Improvements in or relating to fluid bearings |
| WO1992013066A1 (en) | 1991-01-24 | 1992-08-06 | Loyola University Of Chicago | Mammalian cardiac myocyte cell line |
| US5543318A (en) | 1991-06-12 | 1996-08-06 | Smith; David A. | Method of isolation, culture and proliferation of human atrial myocytes |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| US5602301A (en) | 1993-11-16 | 1997-02-11 | Indiana University Foundation | Non-human mammal having a graft and methods of delivering protein to myocardial tissue |
| US6015671A (en) | 1995-06-07 | 2000-01-18 | Indiana University Foundation | Myocardial grafts and cellular compositions |
| DE4441327C1 (de) | 1994-11-22 | 1995-11-09 | Inst Pflanzengenetik & Kultur | Embryonale Herzmuskelzellen, ihre Herstellung und ihre Verwendung |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| ATE322282T1 (de) | 1996-08-16 | 2006-04-15 | Mcw Res Found Inc | Knochen morphogenetisches protein und fibroblasten wachstumsfaktor enthaltende zusammensetzungen und methoden zur induzierung der kardiogenese |
| US20020061837A1 (en) * | 1996-09-05 | 2002-05-23 | Lough John W. | Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| EP0986635A4 (en) | 1997-01-10 | 2001-11-07 | Life Technologies Inc | SERUM SUBSTITUTE FOR EMBRYONIC STEM CELLS |
| US6331406B1 (en) | 1997-03-31 | 2001-12-18 | The John Hopkins University School Of Medicine | Human enbryonic germ cell and methods of use |
| US6099832A (en) | 1997-05-28 | 2000-08-08 | Genzyme Corporation | Transplants for myocardial scars |
| US6110459A (en) | 1997-05-28 | 2000-08-29 | Mickle; Donald A. G. | Transplants for myocardial scars and methods and cellular preparations |
| DK1007631T4 (da) | 1997-07-14 | 2009-04-27 | Osiris Therapeutics Inc | Hjertemuskelregeneration ved anvendelse af mesenkymale stamceller |
| EP1025204A4 (en) | 1997-10-23 | 2001-02-28 | Geron Corp | Methods and materials for the growth of primate-derived primordial stem cells |
| DE19755800A1 (de) | 1997-12-16 | 1999-06-17 | Merck Patent Gmbh | Cyclopeptidderivate |
| JP2002507407A (ja) | 1998-03-23 | 2002-03-12 | ザイモジェネティクス，インコーポレイティド | 心臓由来幹細胞 |
| IL138502A0 (en) | 1998-04-09 | 2001-10-31 | Bresagen Ltd | Cell differentiation/ proliferation and maintenaince factor and uses thereof |
| AU5545499A (en) | 1998-07-31 | 2000-02-21 | Genzyme Corporation | Improvement of cardiac function by mesenchymal stem cell transplantation |
| US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| US20020168766A1 (en) | 2000-01-11 | 2002-11-14 | Gold Joseph D. | Genetically altered human pluripotent stem cells |
| IL129966A (en) | 1999-05-14 | 2009-12-24 | Technion Res & Dev Foundation | ISOLATED HUMAN EMBRYOID BODIES (hEB) DERIVED FROM HUMAN EMBRYONIC STEM CELLS |
| AU783935B2 (en) | 1999-06-18 | 2006-01-05 | Indiana University Research And Technology Corporation | Cardiomyocytes with enhanced proliferative potential, and methods for preparing and using same |
| EP1221956A2 (en) | 1999-09-30 | 2002-07-17 | McGILL UNIVERSITY | Autologous marrow stem cell (msc) transplantation for myocardial regeneration |
| US6280718B1 (en) | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
| AU784618B2 (en) | 1999-12-28 | 2006-05-18 | Kyowa Hakko Kogyo Co. Ltd. | Cells capable of differentiating into heart muscle cells |
| US20020142457A1 (en) | 1999-12-28 | 2002-10-03 | Akihiro Umezawa | Cell having the potentiality of differentiation into cardiomyocytes |
| WO2001051610A1 (en) | 2000-01-14 | 2001-07-19 | Bresagen Limited | Ectoderm cell production |
| EP1248834A4 (en) | 2000-01-21 | 2004-03-17 | Univ Johns Hopkins | CELLS FROM HUMAN EMBRYOID BODIES |
| JP2004504807A (ja) | 2000-03-10 | 2004-02-19 | アドヴァンスト リサーチ アンド テクノロジー インスティチュート、インコーポレイティッド | 多分化能細胞および心筋細胞集団、並びに該集団への経路およびその使用 |
| US20020061587A1 (en) | 2000-07-31 | 2002-05-23 | Piero Anversa | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| AU2001283088A1 (en) | 2000-07-31 | 2002-02-25 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| AU8617301A (en) | 2000-08-01 | 2002-02-13 | Yissum Res Dev Co | Directed differentiation of embryonic cells |
| US6534052B1 (en) | 2000-09-05 | 2003-03-18 | Yong-Fu Xiao | Cardiac function comprising implantation of embryonic stem cell in which differentiation has been initiated |
| US6607720B1 (en) | 2000-09-05 | 2003-08-19 | Yong-Fu Xiao | Genetically altered mammalian embryonic stem cells, their living progeny, and their therapeutic application for improving cardiac function after myocardial infarction |
| JP2004521877A (ja) | 2000-11-22 | 2004-07-22 | ジェロン コーポレイション | 多能性幹細胞の同種移植片の寛容化 |
| AU2002303343A1 (en) | 2001-04-13 | 2002-10-28 | Anterogen Co., Ltd. | Methods and reagents for cell transplantation |
| US7732199B2 (en) * | 2001-07-12 | 2010-06-08 | Geron Corporation | Process for making transplantable cardiomyocytes from human embryonic stem cells |
| IL159580A0 (en) | 2001-07-12 | 2004-06-01 | Geron Corp | Cells of the cardiomyocyte lineage produced from human pluripotent stem cells |
| IL159895A0 (en) | 2001-07-20 | 2004-06-20 | Technion Res & Dev Foundation | Methods of generating human cardiac cells and tissues and uses thereof |
| AU2002317039B2 (en) | 2001-07-24 | 2007-10-04 | Es Cell International Pte Ltd | Methods of inducing differentiation of stem cells |
| EP1463803B1 (en) | 2001-12-07 | 2018-02-14 | Asterias Biotherapeutics, Inc. | Hematopoietic cells from human embryonic stem cells |
| US8298606B2 (en) | 2002-03-08 | 2012-10-30 | The Regents Of The University Of California | Methods and compositions for stabilizing the myocardium |
| US7148062B2 (en) * | 2002-03-15 | 2006-12-12 | Wicell Research Institute, Inc. | Method for generating primate trophoblasts |
| US7247477B2 (en) | 2002-04-16 | 2007-07-24 | Technion Research & Development Foundation Ltd. | Methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells |
| US6898272B2 (en) * | 2002-08-01 | 2005-05-24 | Spirent Communications | System and method for testing telecommunication devices |
| US7569222B2 (en) | 2002-11-18 | 2009-08-04 | Woerly Stephane | Hydrogel membrane composition and use thereof |
| US20050031598A1 (en) | 2002-12-10 | 2005-02-10 | Shulamit Levenberg | Engineering three-dimensional tissue structures using differentiating embryonic stem cells |
| AU2003901099A0 (en) | 2003-03-11 | 2003-03-27 | Es Cell International Pte Ltd. | Methods of inducing differentiation of stem cells |
| US20030224411A1 (en) | 2003-03-13 | 2003-12-04 | Stanton Lawrence W. | Genes that are up- or down-regulated during differentiation of human embryonic stem cells |
| US20050266554A1 (en) * | 2004-04-27 | 2005-12-01 | D Amour Kevin A | PDX1 expressing endoderm |
| US20050142121A1 (en) | 2003-12-24 | 2005-06-30 | Gold Joseph D. | System for improving acceptance of tissue grafts made from embryonic stem cells |
| EP1725654B1 (en) * | 2004-03-19 | 2019-05-01 | Asterias Biotherapeutics, Inc. | Method for making high purity cardiomyocyte preparations suitable for regenerative medicine |
| US7452718B2 (en) | 2004-03-26 | 2008-11-18 | Geron Corporation | Direct differentiation method for making cardiomyocytes from human embryonic stem cells |
| US20050214938A1 (en) | 2004-03-26 | 2005-09-29 | Gold Joseph D | Cardiac bodies: clusters of spontaneously contracting cells for regenerating cardiac function |
| WO2006138718A2 (en) | 2005-06-17 | 2006-12-28 | Drexel University | Three-dimensional scaffolds for tissue engineering made by processing complex extracts of natural extracellular matrices |
| JP2010530955A (ja) | 2006-12-29 | 2010-09-16 | ユニヴァーシティ オブ ワシントン | 二重機能性非汚染表面および材料 |
| WO2009099555A2 (en) | 2008-01-30 | 2009-08-13 | Corning Incorporated | Synthetic surfaces for culturing cells in chemically defined media |
| US9115238B2 (en) | 2009-05-28 | 2015-08-25 | Corning Incorporated | Swellable synthetic microcarriers for culturing cells |
-
2006
- 2006-06-20 KR KR1020137021754A patent/KR20130099253A/ko not_active Ceased
- 2006-06-20 EP EP06785229.3A patent/EP1910518B1/en not_active Not-in-force
- 2006-06-20 WO PCT/US2006/024060 patent/WO2007002136A2/en not_active Ceased
- 2006-06-20 JP JP2008518339A patent/JP5560393B2/ja not_active Expired - Fee Related
- 2006-06-20 AU AU2006262329A patent/AU2006262329B2/en not_active Ceased
- 2006-06-20 US US11/471,916 patent/US9062289B2/en active Active
- 2006-06-20 GB GB0800264A patent/GB2441718B/en not_active Expired - Fee Related
- 2006-06-20 CN CN200680022866.6A patent/CN101228264B/zh not_active Expired - Fee Related
- 2006-06-20 KR KR1020087001452A patent/KR101529317B1/ko not_active Expired - Fee Related
- 2006-06-20 CA CA2611809A patent/CA2611809C/en not_active Expired - Fee Related
-
2007
- 2007-11-25 IL IL187611A patent/IL187611A/en not_active IP Right Cessation
-
2013
- 2013-06-28 JP JP2013135917A patent/JP2013215206A/ja active Pending
-
2015
- 2015-06-22 US US14/746,599 patent/US20150284684A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007002136A3 (en) | 2007-04-19 |
| JP2013215206A (ja) | 2013-10-24 |
| CN101228264B (zh) | 2017-12-26 |
| JP2008543338A (ja) | 2008-12-04 |
| GB2441718B (en) | 2010-10-06 |
| IL187611A (en) | 2012-12-31 |
| WO2007002136A9 (en) | 2008-03-06 |
| AU2006262329B2 (en) | 2011-04-07 |
| AU2006262329A1 (en) | 2007-01-04 |
| KR20080030026A (ko) | 2008-04-03 |
| EP1910518B1 (en) | 2019-05-08 |
| GB2441718A (en) | 2008-03-12 |
| KR20130099253A (ko) | 2013-09-05 |
| US20150284684A1 (en) | 2015-10-08 |
| KR101529317B1 (ko) | 2015-06-16 |
| CA2611809A1 (en) | 2007-01-04 |
| US9062289B2 (en) | 2015-06-23 |
| HK1109913A1 (zh) | 2008-06-27 |
| WO2007002136A2 (en) | 2007-01-04 |
| EP1910518A2 (en) | 2008-04-16 |
| US20070010012A1 (en) | 2007-01-11 |
| EP1910518A4 (en) | 2015-03-11 |
| GB0800264D0 (en) | 2008-02-13 |
| JP5560393B2 (ja) | 2014-07-23 |
| CN101228264A (zh) | 2008-07-23 |
| IL187611A0 (en) | 2008-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2611809C (en) | Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells | |
| US7897389B2 (en) | Direct differentiation method for making cardiomyocytes from human embryonic stem cells | |
| CN1969040B (zh) | 制备适合用于再生医学的高纯度心肌细胞的方法 | |
| US7732199B2 (en) | Process for making transplantable cardiomyocytes from human embryonic stem cells | |
| US20130196436A1 (en) | Cardiomyocyte production | |
| JP5265537B2 (ja) | ヒト胚盤胞由来幹細胞に由来する多能性心臓前駆細胞の新規の集団 | |
| US20050214938A1 (en) | Cardiac bodies: clusters of spontaneously contracting cells for regenerating cardiac function | |
| US20230078230A1 (en) | Methods for the production of committed cardiac progenitor cells | |
| IL178006A (en) | Method for making high purity cardiomyocyte preparations suitable for regenerative medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20220301 |
|
| MKLA | Lapsed |
Effective date: 20200831 |